ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1356	National Cancer Institute	Html	en	Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of metastatic cancer that has spread from an unidentified primary tumor.	general cancer information 0.411851 treatment 0.656267 cancer treatment 0.493001 breast cancer cells 0.486603 primary cancer 0.600191 new cancer treatments 0.408458 Peritoneal Cancer Treatment 0.426103 cancer cells 0.712358 tissue 0.443805 malignant tumor cells 0.423112 body 0.560831 type 0.447878 Cancer Information Service 0.414189 Squamous Neck Cancer 0.400297 PDQ cancer information 0.512966 clinical trial search 0.39505 treatment clinical trials 0.437756 certain changes 0.407705 National Cancer Institute 0.54586 clinical trials 0.823063 normal cells 0.410928 cancer information summary 0.471688 clinical trial 0.588388 new treatment 0.44726	breast cancer prevention 0.400005 primary cancer site 0.517081 cancer tissue 0.403216 patients 0.429603 Cancer Care page 0.397493 PDQ summary 0.435669 treatment clinical trial 0.401935 PDQ Adult Treatment 0.398071 NCI PDQ cancer 0.432436 cancer research process 0.400715 cancer clinical trials 0.44656 tests 0.388491 lymph nodes 0.409196 Unknown Primary Treatment 0.395812 carcinoma 0.39749 primary cancer depend 0.439856 lymph node 0.431668 radiation therapy 0.485838 Treatment Editorial Board 0.413559 cancer information summaries 0.411898 comprehensive cancer information 0.411754 cancer 0.945761 standard treatment 0.426236	CLICK HERE
1570	National Cancer Institute	Html	en	Neuroblastoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood neuroblastoma.	cancer treatment 0.566372 neuroblastoma 0.915175 tumor biology 0.626071 malignant tumor cells 0.558857 body 0.647664 chemotherapy 0.49696 PDQ cancer information 0.548139 clinical trials 0.793699 cancer information summary 0.51948 low-risk neuroblastoma 0.514243 clinical trial 0.659456 high-risk neuroblastoma 0.659347 tumor histology 0.510739 favorable tumor biology 0.542334 unfavorable tumor biology 0.522724 treatment clinical trial 0.493293 lymph nodes 0.501542 radiation therapy 0.646669 Treatment Editorial Board 0.49305 neuroblastoma spreads 0.512002 Neuroblastoma Treatment 0.537187 neuroblastoma cell 0.510315 treatment 0.836037 time neuroblastoma 0.52866 cancer cells 0.648207	recurrent neuroblastoma 0.571181 neuroblastoma talk 0.50906 Neuroendocrine tumor cells 0.542579 neuroblastoma cells 0.566453 treatment clinical trials 0.520878 National Cancer Institute 0.53108 tumor cells 0.633055 intermediate-risk neuroblastoma 0.542626 new treatment 0.533829 Progressive/Recurrent Neuroblastoma 0.502026 primary tumor 0.499207 metastatic tumor 0.511477 blood 0.501083 Iodine 131-MIBG therapy 0.54351 bone marrow 0.53977 stage 4S neuroblastoma 0.523743 cancer clinical trials 0.49476 Recurrent CNS Neuroblastoma 0.519837 stem cell rescue 0.505173 tumor 0.835165 treatment options 0.506317 cancer 0.929691 standard treatment 0.535537 metastatic neuroblastoma 0.513574	CLICK HERE
1675	National Cancer Institute	Html	en	Lymphedema (PDQ®)–Health Professional Version	Expert-reviewed information summary about the anatomy, pathophysiology, clinical manifestations, diagnosis, and treatment of cancer-related lymphedema, a condition in which lymph fluid builds up in tissues and causes swelling.	upper-limb lymphedema 0.596897 Manual lymphatic therapy 0.494091 axillary node dissection 0.485114 lymph nodes. 0.472628 upper-extremity lymphedema 0.68666 arm lymphedema 0.638618 lower-limb lymphedema 0.630542 lymph node dissection 0.832229 lower-extremity lymphedema 0.630897 deep lymphatic systems 0.498654 intestinal lymphatic trunk 0.501781 new lymphedema 0.619269 lumbar lymphatic trunk 0.502509 upper extremity lymphedema 0.623186 manual lymphatic drainage 0.477215 lymph collector vessels 0.497637 lymphatic vessels 0.762836 lymphedema onset 0.622585 secondary lymphedema 0.644407 certified lymphedema 0.696216 left subclavian vein 0.475686 lymphedema manifest 0.633761 lymphedema classification 0.594846 protein-rich lymph fluid 0.533977	secondary lymphatic vessels 0.59679 subclavian lymphatic trunk 0.576658 primary lymphatic vessels 0.596665 subcutaneous lymphatic vessels 0.50703 lymphedema 0.987634 breast cancer patients 0.473019 certified lymphedema therapist 0.652056 patients 0.478875 cancer patients 0.474035 Lymph channels 0.46738 lymph node biopsy 0.634545 breast cancer 0.848001 sentinel lymph node 0.728941 certified lymphedema therapists 0.649954 unidirectional lymphatic flow 0.496065 breast cancer survivors 0.505056 axillary lymph node 0.799687 lymph nodes 0.59192 treatable lymphedema 0.590609 lymph node biopsy. 0.539242 manual lymphedema therapy. 0.64813 lymph node drainage 0.539621 manual lymphedema therapy 0.852751	CLICK HERE
1765	National Cancer Institute	Html	en	Physical Activity and Cancer	A fact sheet that summarizes evidence linking exercise and other physical activity, including work and household chores, to reduced cancer risks.	U. Physical activity 0.367372 bone-strengthening physical activity 0.370971 physical activity daily 0.371076 physical activity attenuate 0.362897 better breast cancer 0.3594 low physical activity 0.37763 Breast Cancer Research 0.357155 muscle-strengthening physical activity 0.370998 vigorous physical activity 0.364437 S. Physical activity 0.365821 average breast cancer 0.365315 cancer risk reduction 0.373439 colorectal cancer 0.41572 average endometrial cancer 0.357301 H. Physical activity 0.366033 postdiagnosis physical activity 0.363749 postmenopausal breast cancer 0.379275 lower risk 0.357009 potential physical activity 0.369413 physical activity influence 0.360893 different cancer risk 0.360424 aerobic physical activity 0.386234 vigorous-intensity physical activity 0.373987 cancer survivors 0.406644 Cancer Epidemiology 0.363652	cancer prevention 0.376861 Physical Activity website 0.371276 A. Physical activity 0.364619 breast cancer diagnosis 0.4205 endometrial cancer risk 0.390992 breast cancer recurrence 0.359315 Physical Activity Guidelines 0.371598 links physical activity 0.369787 physical activity benefit 0.375758 National Cancer Institute 0.363045 daily physical activity 0.370902 L. Physical activity 0.366831 breast cancer risk 0.390634 colon cancer 0.375643 meta-analysis 0.376142 breast cancer 0.54813 colon cancer risk 0.372667 systematic review 0.435657 physical activity 0.996162 prostate cancer 0.369869 leisure-time physical activity 0.442557 et al 0.539243 cancer risk 0.441434 recreational physical activity 0.391568	CLICK HERE
2068	National Cancer Institute	Html	es	Marcadores de tumores	Hoja informativa que explica lo que son los marcadores de tumores y responde preguntas sobre su uso para el diagnóstico y tratamiento del cáncer.	Bast RC Jr 0.727949 cancer screening 0.603977 Gray RJ 0.462067 randomized european study 0.51305 Asociación Estadounidense 0.468124 estudio plco 0.461327 Bigbee W 0.467579 amplia gama 0.464843 afecciones benignas 0.671952 Herberman RB 0.469893 Prevention Research 0.463207 BC Decker Inc 0.509079 Clinical Laboratory Improvement 0.519898 Cancer Screening Randomized 0.544857 Controlled Trial 0.467216 riesgo intermedio 0.462476 Clinical Practice 0.47196 ecografía transvaginal 0.471751 Makower DF 0.466396 estudio tailorx 0.460805 ¿Cuáles marcadores 0.637902 21-gene expression assay 0.514014	Hugosson J 0.463892 Instituto Nacional 0.461324 screening trial specimens 0.541412 Oncología Clínica 0.463202 tumor markers 0.619108 Andriole G 0.463781 Mortality results from 0.526447 Quality Requirements 0.470424 Kufe DW 0.468535 Black A 0.461077 6th ed 0.467056 Oncotype DX® 0.469566 situaciones benignas 0.492829 PubMed Abstract 0.928354 tratamientos resultantes 0.466203 Buys SS 0.460749 Bioquímica Clínica 0.461341 Pollock RE 0.46616 New England Journal 0.930005 Roobol MJ 0.466517 Sparano JA 0.466154 hoja informativa estadificación 0.539118	CLICK HERE
2079	National Cancer Institute	Html	es	BRCA1 y BRCA2: Riesgo de cáncer y pruebas genéticas	Hoja informativa acerca de los genes BRCA1 y BRCA2, de qué hacer si una persona tiene resultados positivos para una de estas alteraciones, y de las consecuencias de las pruebas genéticas.	with inherited mutations 0.40971 Fanconi anemia 0.442696 general padecerán cáncer 0.476912 Lubinski J 0.414965 Cancer Statistics Review 0.41308 brca1 or brca2 0.539593 largo plazo 0.414755 American Cancer Society 0.413258 posibles perjuicios 0.41059 Biallelic mutations 0.410182 National Comprehensive Cancer 0.413868 Breast Cancer Research 0.418728 with brca1 or 0.423664 Múltiples cánceres 0.410805 mutaciones específicas dañinas 0.471623 brca2 mutations 0.589927 among male brca1 0.421616 or genetic predisposition 0.416124 BRCA2 padecerán 0.44228 gen palb2 0.413362 BRCA1 mutation carriers 0.444383 Estados Unidos 0.427518 padecerán cáncer 0.566332 mutaciones dañinas 0.851633 PubMed Abstract 0.989166	mutation carriers identified 0.410419 seno masculino 0.429589 Clinical Oncology 0.441136 BRCA2 carriers 0.419799 risks among brca1 0.420776 BRCA2 mutation carriers 0.508942 BRCA2 mutations detected 0.422577 contralateral breast 0.413156 National Cancer Institute 0.442375 Cancer Research 0.430441 Breast Cancer Prevention 0.417323 antecedentes familiares 0.783866 or brca2 mutations 0.503006 mutation carriers with 0.423928 breast cancer 0.531052 clinical breast examination 0.410267 mujeres padecerán 0.409393 mujeres portadoras 0.421608 gen brca1 0.536899 asesoría genética 0.435987 cancer risk 0.445775 New England Journal 0.415366 bilateral profiláctica 0.437879 BRCA2 mutations account 0.4223	CLICK HERE
16716	National Cancer Institute	Html	en	NCI Cancer Moonshot℠ Public Access and Data Sharing Policy	NCI has established a data sharing policy that supports open, public access to all research and data for projects funded as part of the Cancer Moonshot. Find details on the policy.	Underlying Primary Data 0.835591 National Cancer Advisory 0.204571 Creative Commons 0.266314 Cancer Moonshotâ„  0.229846 Moonshot Research Project 0.326921 public domain tool 0.238273 extramural Cancer Moonshot 0.217832 Cancer Moonshot beginning 0.210573 cancer research 0.226051 Data Sharing Repositories 0.219342 underlying data 0.223365 NIH Sharing Policies 0.206938 Genomic Data Sharing 0.238331 Moonshot Research Projects 0.712789 Cancer Moonshotâ„  Research 0.221203 NIH Data Sharing 0.283755 National Cancer Institute 0.205263 Cancer Moonshot Projects 0.211704 public access 0.827988	Blue Ribbon Panel 0.23172 Cancer Moonshot Research 0.963477 independent data access 0.222133 data sharing policies 0.240205 Public Access Policy. 0.214656 nih public access 0.329101 Genomic Data Commons 0.208284 Enhanced Data Sharing 0.250631 Public Access Policy 0.237717 NCI-Supported Cancer Moonshot 0.379658 appropriate Public Access 0.254192 cancer research projects 0.217712 NCI researchers 0.205129 NCI intramural Cancer 0.231006 Data Sharing Policy 0.330676 Rule.7 Underlying Primary 0.217644 Data Sharing Plan 0.965755 intramural Cancer Moonshot 0.258314 Cancer Moonshot Public 0.244424	CLICK HERE
16848	National Cancer Institute	Html	en	Treatment and Therapy	Nanotechnology offers the means to target therapies directly and selectively to cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. Futhermore, surgical resection of tumors can be guided and enhanced by way of nanotechnology tools. Find out how nanotechnology will offer the next generation of our therapeutic arsenal to the patient.	cancer treatment 0.854097 tumor type 0.82492 tumor tissues 0.889211 Cancer therapies 0.820703 large surface area 0.827043 nanoparticles 0.943843 superficial tumor 0.871555 nanotechnology cancer therapy 0.925806 multiple myeloma patients 0.821624 RNA-based genetic therapeutics 0.82576 cancer therapeutics 0.879587 vivo RNA nanoparticle 0.839578 nucleic acids 0.851966 electromagnetic radiation modalities 0.829021 cancer immunotherapy deepens 0.869884 artificial antigen 0.824529 Host Cell Response 0.906892 radiation therapy 0.999924 Standalone nanoparticle vaccines 0.835115 multiple dendritic cell 0.822099 conventional radiation therapy 0.856977 tumor vasculature permeability 0.888964 Cancer Nanotechnology Excellence 0.870289 tumor mass 0.82439	photodynamic therapy 0.836532 Cancer Nanotechnology awardees 0.958295 cancer cells 0.999243 external radiation sources 0.839028 small molecule compounds 0.820814 Cancer Therapy Center 0.956254 form Cherenkov radiation 0.829553 tumor accumulation 0.82268 atomic number nanoparticles 0.859022 Biology Cancer Center 0.860679 current radiotherapy dosage 0.82716 delivery 0.878526 combination drug delivery 0.856304 current treatment modalities 0.839227 superficial tumor sites 0.867918 innovative nanoparticle packages 0.854373 Gene silencing therapeutics 0.826818 tissue tumor targets 0.869042 electromagnetic radiation 0.829381 nanomaterial-based delivery platforms 0.862296 external electromagnetic radiation 0.823812 tumor 0.913691 tumor microenvironment 0.865684 deep tissue tumors 0.824773	CLICK HERE
16886	National Cancer Institute	Html	en	Thyroid Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for thyroid cancer.	thyroid cancer trends 0.476323 thyroid tumors 0.422645 United States 0.468063 thyroid cancer screening. 0.46539 cancer registry data 0.363099 thyroid fine-needle aspiration 0.447959 opportunistic thyroid cancer 0.46743 thyroid cancer 0.931034 thyroid cancer incidence 0.631162 Thyroid Cancer Treatment 0.500772 Well-differentiated thyroid cancers 0.495048 palpation screening results 0.370878 total thyroidectomy 0.358528 cancer screening results 0.386186 radioactive iodine 0.350234 South Korea 0.456219 10-year relative survival 0.451331 frequently diagnosed cancer 0.37852 recurrent laryngeal nerve 0.36801 papillary thyroid cancer 0.525506 summary event measure 0.364067 free screening exams 0.364504 follicular thyroid cancers 0.495803 thyroid cancer mortality 0.490522	thyroid cancer overdiagnosis 0.479797 neck palpation 0.364787 cancer incidence rates 0.389027 thyroid cancer deaths. 0.489306 thyroid cancers cases 0.461202 thyroid cancer cases 0.467037 papillary thyroid cancers 0.524728 cancer diagnoses 0.354076 anaplastic thyroid cancers 0.495303 laryngeal nerve injury 0.368292 thyroid cancer screening 0.828908 thyroid cancers 0.597668 thyroid ultrasound 0.428817 suspicious screening result 0.361018 thyroid surgery 0.435882 population-based screening programs 0.366887 national cancer screening 0.412147 medullary thyroid cancer 0.491568 Cancer Screening Guidelines 0.39228 formal screening 0.347128 asymptomatic thyroid cancers 0.481523 incidental thyroid nodules 0.466527 vocal cord 0.353855	CLICK HERE
17234	National Cancer Institute	Html	en	Adding Immune-based Treatments to Standard Glioblastoma Therapy	This clinical trial is testing standard therapy (surgery, radiation and temozolomide) plus immunotherapy with pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.	immune checkpoint inhibitor 0.991382 Dr. Gilbert 0.728039 tumor tissue 0.405841 trial contact information 0.29929 experimental vaccine 0.247456 1-year overall survival 0.300393 NCI’s Cancer 0.233291 Treating Patients 0.208707 little tumor tissue 0.376059 standard therapy plus 0.329661 immune response 0.550076 NCI Clinical Trials 0.330246 chemotherapy drug temozolomide 0.399109 cancer treatment vaccine 0.66133 primary brain tumor 0.428278 Cancer Research 0.215559 clinical trials 0.480839	slow tumor growth 0.416918 partially randomized phase 0.30891 patients 0.251176 Mark R. Gilbert 0.399405 tumor-specific vaccine 0.249165 experimental cancer treatment 0.582716 immune checkpoint inhibitors 0.542772 microscopic tumor 0.266367 newly diagnosed glioblastoma 0.842005 Current standard therapy 0.36143 placebo vaccine 0.253985 immunotherapy drug pembrolizumab 0.351275 median survival time 0.347591 protocol summary 0.359999 radiation therapy 0.342013 standard therapy 0.747186	CLICK HERE